That study also demonstrated that a GLP-1R/GCGR dual agonist induced body weight loss across species, which is promising for ALT-801 development to treat NASH and the accompanying liver fibrosis. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.